Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation-Reference-Cited by-同舟云学术

Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation

Published:2024-05-14 Issue:9 Volume:102 Page:
ISSN:0028-3878
Container-title:Neurology
language:en
Short-container-title:Neurology

Author:

Dittrich Anna¹^ORCID,Westman Eric¹^ORCID,Shams Sara¹,Skillbäck Tobias¹,Zetterberg Henrik¹^ORCID,Blennow Kaj¹^ORCID,Zettergren Anna¹,Skoog Ingmar¹^ORCID,Kern Silke¹

Affiliation:

1. From the Neuropsychiatric Epidemiology Unit (A.D., T.S., A.Z., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Division of Clinical Geriatrics (E.W.), Department of Neurobiology, Care Sciences and Society (NVS), Karolinska University Hospital, Stockholm, Sweden; Department of Neuroimaging (E.W.), Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Link

https://www.neurology.org/doi/pdfdirect/10.1212/WNL.0000000000209402

Reference15 articles.

1. Alzheimer's disease

2. Full Prescribing Information, LEQEMBI®. 7/2023. ed: U.S. Food and Drug Administration; 2023. Accessed October 7, 2023. accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s001lbl.pdf

3. Lecanemab in Early Alzheimer’s Disease

4. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

5. The Gothenburg H70 Birth cohort study 2014–16: design, methods and study population

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aβ-Amyloid Lowering with Monoclonal Antibodies for Alzheimer's Disease: Appropriate Use Recommendations for Australasian Conditions;SSRN Electronic Journal;2024